To include your compound in the COVID-19 Resource Center, submit it here.

Ahead of 2019 milestones, Aslan reduces headcount, operating costs

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Jan. 29 it will reduce headcount by 30% and slash operating costs by 50%.

The restructuring will help support Aslan well into 2020 as it focuses operations

Read the full 338 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE